Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents (Q37968485)

22169996

26 August 2017

title

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Philippe A Gallay

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

15 May 2020

publication date

1 June 2012

1 reference

26 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

15 May 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

15 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

15 May 2020

page(s)

200-210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

American Gastroenterological Association technical review on the management of hepatitis C.

15 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Epidemiology of hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Current and future management of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Comparing the public health burden of chronic hepatitis C and HIV infection in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Protease and polymerase inhibitors for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin inhibitors in hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

21 January 2018

Cyclophilin inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

New direct-acting antivirals in the development for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Development of novel antiviral therapies for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

New hepatitis C therapies in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Specific inhibition of hepatitis C virus replication by cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Multiple cyclophilins involved in different cellular pathways mediate HCV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin: a specific cytosolic binding protein for cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Catalysis of protein folding by prolyl isomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Conformational specificity of chymotrypsin toward proline-containing substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Emerging drugs for hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8263-5

Cyclophilin inhibitors for the treatment of HCV infection.

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

1 reference

12 December 2020

Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.

1 reference

12 December 2020

Cyclosporine: a new and promising immunosuppressive agent

1 reference

12 December 2020

10.1007/S12026-011-8263-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6634313&resulttype=core&format=json

15 May 2020

22169996

1 reference